Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
COVID-19의 항응고: Enoxaparin, Heparin 및 Apixaban이 사망률에 미치는 영향
Article
[키워드] 2019
48 hour
48 hours
adjusted
Admission
age
Analysis
analyzed
Anticoagulant
Anticoagulants
anticoagulation
anticoagulation therapy
apixaban
benefit
categories
clinical trial
cohort study
Comorbidity
coronavirus
coronavirus disease
COVID-19
D-dimer
D-dimer level
D-dimer levels
decrease
decreased mortality
demonstrated
disease
disease severity
Effect
Efficacy
enoxaparin
entire cohort
filtration rate
Gender
glomerular filtration rate
heparin
Hospitalization
Illness severity
IMPROVE
increased mortality
Increases
increases in
Inpatients
intensive care
intensive care unit admission
intention-to-treat
Logistic regression
Logistic regression analyses
Mortality
no increase
Odds ratio
oxygen
oxygen saturation
parameters
Patient
patients with moderate
Prophylactic
prothrombotic
significant decrease
stratified
survival
therapy
Ventilation
[DOI] 10.1055/s-0040-1720978 PMC 바로가기 [Article Type] Article
[DOI] 10.1055/s-0040-1720978 PMC 바로가기 [Article Type] Article